MJ-NR-27
MJ-NR-27 is a bifunctional small molecule of ribonuclease-targeting chimera (RIBOTAC) that targets NRAS mRNA containing a G-quadruplex structure. MJ-NR-27 uses RNase L ligand 3 (HY-177030) as the RNase L ligand, RNA binder 4 (HY-183981) as the RNA binder, and Bis-PEG3-acid (HY-126891) as the linker. MJ-NR-27 achieves target RNA degradation by recruiting ribonuclease RNase L, and significantly induces morphological changes in tumor cells. MJ-NR-27 can be used in cancer research.
For research use only. We do not sell to patients.
- Formula: C60H66N10O7S
- Molecular Weight:1071.29
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All DNA/RNA Synthesis Isoforms
More
Biological Activity
MJ-NR-27 (compound 5) (10 μM; 24-72 h) reduces G4-containing NRAS mRNA levels by ~25% in MDA-MB-231 human breast adenocarcinoma cells, without affecting total NRAS mRNA levels[1].
MJ-NR-27 (10-40 μM; 24-72 h) exhibits marginal G4-containing NRAS mRNA degradation activity in MCF-7 human breast adenocarcinoma cells[1].
MJ-NR-27 (1-10 μM; 48 h) does not significantly alter NRAS protein expression in MCF-7 human breast adenocarcinoma cells[1].
MJ-NR-27 (0.46-46 μM; 72 h) exhibits no significant cytotoxicity in MCF-7 and MDA-MB-231 human breast adenocarcinoma cells after 72 h of incubation[1].
MJ-NR-27 (3-50 μM; 20 h) induces concentration-dependent cellular morphological changes in U2OS human osteosarcoma cells, with induction values ranging from 13% at 3 μM to 53.7% at 50 μM, and represents a new biological cluster with unique modes of action[1].
MJ-NR-27 (10 μM; 48 h) alters the transcriptomic profile of MCF-7 human breast adenocarcinoma cells, with significant upregulation of 5 genes and downregulation of 11 genes, including multiple cancer-associated targets[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231 human breast adenocarcinoma cells
-
Concentration:10 μM
-
Incubation Time:24 h, 48 h, 72 h
-
Result:Reduced G4-NRAS mRNA levels by approximately 25% compared to vehicle control.
Showed no significant effect on total NRAS mRNA levels.
-
Cell Line:MCF-7 human breast adenocarcinoma cells
-
Concentration:10 μM, 40 μM
-
Incubation Time:24 h, 48 h, 72 h
-
Result:Showed marginal G4-NRAS mRNA degradation activity, consistent with results observed in MDA-MB-231 cells.
-
Cell Line:MCF-7 human breast adenocarcinoma cells
-
Concentration:1 μM, 10 μM
-
Incubation Time:48 h
-
Result:Showed no significant changes in NRAS protein levels relative to vehicle control.
Chemical Information
-
Molecular Weight 1071.29
-
Formula C60H66N10O7S
-
SMILES
CNC([C@H](C1=CC=CC=C1)N(C)CC2=CC=C(C3=CC(C4=C(NC(CCOCCOCCOCCC(N5CCN(CCNC6=NC(C7=NN=C(C8=CC=C(C)C=C8)O7)=NC9=C6C=CC=C9)CC5)=O)=O)C=CS4)=CC=C3)C=C2)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
MJ-NR-27 Related Classifications
HY-183980 Related Classifications
Powered by Bioz
- MJ-NR-27
- RIBOTAC
- G-quadruplex
- DNA/RNA Synthesis
- transcriptomic profile
- NRAS mRNA
- NRAS protein
- human osteosarcoma cells
- breast cancer cells
- U2OS human osteosarcoma cells
- cancer-associated targets
- MCF-7 human breast adenocarcinoma cells
- MDA-MB-231 human breast adenocarcinoma cells
- total NRAS mRNA
- Inhibitor
- inhibitor
- inhibit